Any current/future capex/capital investment/strategic investment?

The company has a capex plan of around INR 200 crores over the next few years. Capex is divided into three key areas: R&D center, API block, and fermentation block. The API block and R&D labs are expected to be operational by June-July of the current financial year. Fermentation block expansion (additional 550 cubic meters capacity) will be completed by June-July of the next financial year (FY 2024). INR 40 crores of the API block capex is expected to be spent by July. Advances have been paid to capital equipment suppliers, with expenditures to be capitalized as assets progress. The capex focu

Future growth expectations in sales/revenue/volumes?

The company is targeting about 25% growth in sales/revenue for the next financial year (FY 2024) (Page 17, Sachin Patel). Sales volumes have been consistent, with production maintained at about 75-100% capacity, expecting to run at 100% capacity this year (Page 7). Tuberculosis tender-driven market delays have impacted recent sales, especially Rifa-S, but tenders are expected to open in next two quarters, leading to significant volume increase (Pages 4, 6, 7). The new API block, expected to be operational by June-July 2023, will aid in achieving 25-30% growth and diversify product base (Page 1

Future growth expectations in earnings/operating earnings/profits/EPS?

The company is targeting approximately 25% growth in business for the next financial year (FY24) as stated by Sachin Patel. Despite sales fluctuations in Q3 due to tender delays, production levels remain high, with the expectation that tenders will open and boost volumes soon. Nine-month revenue and profit for the current fiscal year have already surpassed previous financial year levels. EBITDA margin for the nine months stands at 49.1%, with PAT growing 36.7% year-on-year. The new API block and R&D facility expected to start by June-July 2023 are anticipated to contribute to growth.

Current/ Expected Orderbook/ Pending Orders?

The company acknowledged delays in government and global tenders, particularly impacting Rifamycin-S sales, as it is a tender-driven segment. Despite subdued sales in the recent quarter, production levels have been maintained to build inventory in anticipation of tender finalizations. Management expects the tuberculosis market tenders to open up in the next two quarters, leading to significant volume increases. Sales momentum is expected to stabilize and improve as tender processes finalize. There was no specific mention of a quantified current order book or pending orders value during the cal

Gujarat Themis BiosynQ3 FY23Pharmaceuticals & Biotechnology

Gujarat Themis Biosyn Q3 FY23 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹388.65P/E: 104.2Market Cap: ₹5.1K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 2

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 2

The company is targeting about 25% growth in sales/revenue for the next financial year (FY 2024) (Page 17, Sachin Patel).
Sales volumes have been consistent, with production maintained at about 75-100% capacity, expecting to run at 100% capacity this year (Page 7).
Tuberculosis tender-driven market delays have impacted recent sales, especially Rifa-S, but tenders are expected to open in next two quarters, leading to significant volume increase (Pages 4, 6, 7).
The new API block, expected to be operational by June-July 2023, will aid in achieving 25-30% growth and diversify product base (Page 10).
The company is expanding fermentation capacity from 450 to 1000 cubic meters and increasing R&D efforts, which supports future growth (Pages 4, 17).
Emphasis on ROI for new projects over turnover indicates measured scaling with a focus on profitability (Page 9).

Margin guidance

Category 3

The company is targeting approximately 25% growth in business for the next financial year (FY24) as stated by Sachin Patel.
Despite sales fluctuations in Q3 due to tender delays, production levels remain high, with the expectation that tenders will open and boost volumes soon.
Nine-month revenue and profit for the current fiscal year have already surpassed previous financial year levels.
EBITDA margin for the nine months stands at 49.1%, with PAT growing 36.7% year-on-year.
The new API block and R&D facility expected to start by June-July 2023 are anticipated to contribute to growth.
EPS for nine months stands at INR 31.85, with quarterly EPS at INR 6.75.
R&D expenses may increase as a percentage of sales to maintain competitive advantage, supporting future earnings growth.
The capex plan of INR 200 crores over 2-3 years aims for healthy ROI rather than specific turnover targets.

See what Gujarat Themis Biosyn management said on margin guidance — free account, 30 seconds.

Fundraise plans

The transcript does not mention any current or planned fundraising through debt or equity. Specifically: - There is no discussion or indication of raising funds via equity or debt during the call. - The company focuses on using internal resources and capex plans for growth (INR 200 crores over next 2-3 years). - Capex expenditures (INR 14 crores spent, INR 13 crores in CWIP) indicate ongoing investments funded internally. - Management emphasizes ROI-based expansion rather than targeting fundraising. - Investor relations are available for follow-up, but no mention of fundraising queries or plans. Hence, based on this transcript, Gujarat Themis Biosyn Limited has not announced any current or future fundraising via debt or equity.

Order book

The company acknowledged delays in government and global tenders, particularly impacting Rifamycin-S sales, as it is a tender-driven segment.
Despite subdued sales in the recent quarter, production levels have been maintained to build inventory in anticipation of tender finalizations.
Management expects the tuberculosis market tenders to open up in the next two quarters, leading to significant volume increases.
Sales momentum is expected to stabilize and improve as tender processes finalize.
There was no specific mention of a quantified current order book or pending orders value during the call.
The company advised investors to contact the Investor Relations team for detailed follow-ups regarding orders.

See what Gujarat Themis Biosyn management said on order book — free account, 30 seconds.

Capex plans

Yes

The company has a capex plan of around INR 200 crores over the next few years.
Capex is divided into three key areas: R&D center, API block, and fermentation block.
The API block and R&D labs are expected to be operational by June-July of the current financial year.
Fermentation block expansion (additional 550 cubic meters capacity) will be completed by June-July of the next financial year (FY 2024).
INR 40 crores of the API block capex is expected to be spent by July.
Advances have been paid to capital equipment suppliers, with expenditures to be capitalized as assets progress.
The capex focus prioritizes ROI and efficient project completion over just turnover growth.
Strategic aim includes expanding product basket through new APIs and fermentation products to diversify revenue sources.

Track Gujarat Themis Biosyn — get its next earnings analysis in your feed

How does Gujarat Themis Biosyn rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

ThisGujarat Themis Biosyn

Rev 2Mar 3

See where Gujarat Themis Biosyn sits in Pharmaceuticals & BiotechnologySee which companies these are, and every other name in the sector.Open rankings

How does Gujarat Themis Biosyn rank in Pharmaceuticals & Biotechnology?

Compare Gujarat Themis Biosyn against every Pharmaceuticals & Biotechnology company (Q3 FY23) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

What Gujarat Themis Biosyn's management said in earlier quarters

Earlier calls (5)

Others in Pharmaceuticals & Biotechnology this season

Natural Capsules (Q2 FY27)
11.67% increase. Key results statement takeaways from Natural Capsules Ltd's Q2 FY27 results statement — and how it ranks against sector peers.
Sotac Pharmaceuticals (Q2 FY27)
7,654.95 lakhs; Operating margin ≈ 10.68% for HY Sep 2026 . Key results statement takeaways from Sotac Pharmaceuticals Ltd's Q2 FY27 results statement — and how
Bio Medica Lab (Q2 FY27)
EBITDA for the quarter:** ₹510 lakhs, up 25% year-on-year (YoY). Key results statement takeaways from Bio Medica Laboratories Ltd's Q2 FY27 results statement —
Syncom Formulations (India) (Q2 FY27)
Quarterly Revenue (Q2 FY 2026-27 ended 30/09/2026):** ₹14,821.08 lakhs (Unaudited) . Key results statement takeaways from Syncom Formulations (India) Ltd's Q2 F

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →